{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Hyperlipidemia&page=2",
    "query": {
      "condition": "Mixed Hyperlipidemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mixed+Hyperlipidemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:27:24.146Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01968954",
      "title": "Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Bococizumab (PF-04950615;RN316)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 711,
      "start_date": "2013-10",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2017-05-17",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01968954"
    },
    {
      "nct_id": "NCT04516291",
      "title": "A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "Hyperlipidemias",
        "Hyperlipoproteinemias"
      ],
      "interventions": [
        {
          "name": "Vupanorsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 286,
      "start_date": "2020-09-28",
      "completion_date": "2021-12-06",
      "has_results": true,
      "last_update_posted_date": "2022-10-04",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 59,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Lincoln, California + 35 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lincoln",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04516291"
    },
    {
      "nct_id": "NCT02275156",
      "title": "Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2014-08-19",
      "completion_date": "2014-12-19",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275156"
    },
    {
      "nct_id": "NCT07592858",
      "title": "Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "PFAS",
        "Environmental Exposures",
        "Occupational Exposure to Chemicals",
        "Military Exposure",
        "Burn Pit Exposure",
        "Forever Chemicals",
        "Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia",
        "Hyperlipidemia (E.G., Hypercholesterolemia)"
      ],
      "interventions": [
        {
          "name": "Colesevelam",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-07-01",
      "completion_date": "2029-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Augusta, Maine",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Augusta",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07592858"
    },
    {
      "nct_id": "NCT01763866",
      "title": "LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2067,
      "start_date": "2013-01-15",
      "completion_date": "2013-12-04",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Carmichael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763866"
    },
    {
      "nct_id": "NCT01849497",
      "title": "Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hypercholesterolemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab Pre-filled Syringe",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evolocumab AI/pen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 149,
      "start_date": "2013-04-18",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 21,
      "location_summary": "Encino, California • Thousand Oaks, California • Ventura, California + 17 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        },
        {
          "city": "Westlake Village",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01849497"
    },
    {
      "nct_id": "NCT01879319",
      "title": "Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Hypercholesterolemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab AMD",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Evolocumab AI/pen",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 164,
      "start_date": "2013-07-11",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879319"
    },
    {
      "nct_id": "NCT02100514",
      "title": "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Bococizumab (PF-04950615; RN316)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 746,
      "start_date": "2014-10-28",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-07-31",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 108,
      "location_summary": "Alexander City, Alabama • Auburn, Alabama • Phoenix, Arizona + 72 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Auburn",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02100514"
    },
    {
      "nct_id": "NCT00345657",
      "title": "Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperlipidemia",
        "Mixed Hyperlipidemia",
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "Niacin Extended Release/Lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "In His Image",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2003-07",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2006-06-28",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 1,
      "location_summary": "Tulsa, Oklahoma",
      "locations": [
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345657"
    },
    {
      "nct_id": "NCT00309712",
      "title": "Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type II Diabetes Mellitus",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "fenofibrate 160 mg and placebo",
          "type": "DRUG"
        },
        {
          "name": "simvastatin 20 mg and placebo",
          "type": "DRUG"
        },
        {
          "name": "fenofibrate 160 mg and simvastatin 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Intermountain Health Care, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2002-08",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2008-08-21",
      "last_synced_at": "2026-07-22T16:27:24.146Z",
      "location_count": 2,
      "location_summary": "Ogden, Utah • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Ogden",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00309712"
    }
  ]
}